Media headlines about XOMA Corporation (NASDAQ:XOMA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. XOMA Corporation earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 44.5954060276245 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have impacted Accern’s scoring:

XOMA has been the subject of several recent analyst reports. Zacks Investment Research downgraded shares of XOMA Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, May 9th. HC Wainwright began coverage on shares of XOMA Corporation in a report on Monday, June 12th. They set a “buy” rating and a $15.00 target price for the company. ValuEngine upgraded shares of XOMA Corporation from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 12th. Finally, Wedbush restated a “hold” rating on shares of XOMA Corporation in a report on Monday, August 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. XOMA Corporation currently has a consensus rating of “Hold” and a consensus target price of $10.67.

Shares of XOMA Corporation (XOMA) traded up 0.90% on Friday, reaching $11.19. 27,951 shares of the company’s stock were exchanged. The firm’s 50 day moving average price is $7.93 and its 200-day moving average price is $6.74. The company’s market capitalization is $85.02 million. XOMA Corporation has a 12 month low of $3.96 and a 12 month high of $13.98.

COPYRIGHT VIOLATION WARNING: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-xoma-corporation-xoma-stock-price/1536623.html.

XOMA Corporation Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Insider Buying and Selling by Quarter for XOMA Corporation (NASDAQ:XOMA)

Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.